ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 939

Shared High Risk of Intensive Care Unit Admission in Three Autoimmune Inflammatory Diseases

Christine Peschken1, Carol A. Hitchon2, Allan Garland3, Charles N. Bernstein3, Randy Fransoo4 and Ruth Ann Marrie3, 1Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 4Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Autoimmune diseases and comorbidity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Little is known about the influence of autoimmune inflammatory diseases on the risk of critical illness, as defined by Intensive care unit admissions (ICU). Using a large, population-based dataset we determined the incidence of ICU admissions in rheumatoid arthritis (RA), multiple sclerosis (MS) and inflammatory bowel disease (IBD). These conditions are highly prevalent in Western countries and often managed with immunomodulatory therapies.

Methods:

In a stable population of over 900,000 adults, hospital claims from an administrative database were linked to a population based ICU database to determine the incidence of ICU admissions from 2000-2010. RA, MS, and IBD patients were compared to cohorts from the general population, matched on sex, year of birth and region of residence, with up to 5 controls per case. Individuals with any diagnostic codes (ICD-9/10) for autoimmune inflammatory disease were excluded from the control cohorts. We used previously published and validated definitions for RA, MS, and IBD. Annual incidence rates were estimated by age group, sex, and geographic region (number of persons in each cohort with at ≥ 1ICU admission/ number of persons alive in that cohort at year-end).  Results were age and sex standardized to the general Canadian population. The incidence of ICU admission between the disease specific cohorts and matched cohorts were compared using incidence rate ratios (IRR). The 10 year cumulative incidence of ICU admission for the period 2000-2010 was compared: (number of persons with disease who had ≥ 1 episode of critical illness/ person-years at risk).  Hazard ratios for the 10 year period were calculated after adjustment for age, sex, socioeconomic status and comorbidity.

Results:

The annual incidence rates of ICU admission over the 10 year period were:  RA 0.82-1.18%; MS 0.51-1.07%; and IBD 0.55-1.12%, compared to the matched cohorts; 0.32-0.60%. The IRR for the 10 year cumulative incidence rate was 1.62 (95% CI 1.46-1.80) for RA; 1.54 (95% CI 1.30-1.77) for MS; 1.52 (95% CI 1.36-1.68) for IBD. Hazard ratios over the 10 year period for the 3 diseases were: RA HR=1.86 (95%CI 1.68-2.05); MS HR= 1.65 (95%CI 1.36-2.01); IBD HR= 2.02 (95%CI 1.78-2.28).          

Conclusion:   The risk of ICU admission is significantly increased in RA, MS and IBD patients compared to the general population. Close to 1% of adults with these diseases develop critical illness each year; representing a substantial cost to the healthcare system.  The risks between the 3 diseases are remarkably similar, suggesting shared risks from chronic inflammation and/or immunomodulatory therapy.

 


Disclosure:

C. Peschken,
None;

C. A. Hitchon,
None;

A. Garland,
None;

C. N. Bernstein,
None;

R. Fransoo,
None;

R. A. Marrie,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/shared-high-risk-of-intensive-care-unit-admission-in-three-autoimmune-inflammatory-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology